Chester County News and Community Website
PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) has shared its financial results for the first quarter of 2025, along with updates on its ongoing clinical programs and operational advancements. …
Passage Bio Reports Q1 2025 Financial Results and Highlights Progress in Gene Therapy Development Read More PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) announced its 2024 financial results, highlighting progress in its PBFT02 gene therapy program for frontotemporal dementia (FTD) associated with GRN mutations (FTD-GRN) …
Passage Bio Reports 2024 Financial Results and Advances in PBFT02 Program Read More PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) has announced its participation in two upcoming investor conferences, where management will share updates on the company’s progress and engage with stakeholders.
Passage Bio to Present at Two Major Investor Conferences Read More PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) has shared updated findings from its ongoing Phase 1/2 upliFT-D clinical trial, which evaluates PBFT02 as a potential treatment for frontotemporal dementia …
Passage Bio Reports Promising Data in Trial for Frontotemporal Dementia Treatment Read More